In a report released today, Matthew Lillis from Cantor Fitzgerald maintained a Buy rating on Taiwan Liposome Company Ltd (TLC), with a price target of $11. The company’s shares closed on Friday at $5.82, close to its 52-week low of $5.02.
Lillis wrote:
“We believe TLC’s expertise in applying liposome science is creating novel medicines with enhanced properties that target areas of unmet medical need. The company’s liposome-based formulation technologies, in our view have the potential to improve the pharmacologic and therapeutic potential of approved pharmacophores to treat various medical disorders. The company has developed four diverse lead product candidates in pain management, ophthalmology, and oncology that are advancing into late-stage clinical trials.”
According to TipRanks.com, Lillis is a 1-star analyst with an average return of -2.1% and a 33.3% success rate. Lillis covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Evofem Biosciences Inc, and Amag Pharmaceuticals.
Taiwan Liposome Company Ltd has an analyst consensus of Strong Buy, with a price target consensus of $10.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11 and a one-year low of $5.02. Currently, Taiwan Liposome Company Ltd has an average volume of 8,143.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Taiwan Liposome Co., Ltd. engages in the authorized cooperative development of special medicine as well as new formulation and prescription drugs. Its products include pain management, ophthalmology, and oncology related drugs based on lipid drug delivery system. It also provides royalties and biotechnology services.
